

Stanislava D StoÅiÄ-GrujiÄiÄ

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7106882/publications.pdf>

Version: 2024-02-01

119
papers

3,761
citations

109321

35
h-index

149698

56
g-index

121
all docs

121
docs citations

121
times ranked

4973
citing authors

#	ARTICLE	IF	CITATIONS
1	MIF and insulin: Lifetime companions from common genesis to common pathogenesis. <i>Cytokine</i> , 2020, 125, 154792.	3.2	6
2	Orally delivered all-trans-retinoic acid- and transforming growth factor- β^2 -loaded microparticles ameliorate type 1 diabetes in mice. <i>European Journal of Pharmacology</i> , 2019, 864, 172721.	3.5	17
3	Protective effects of carbonyl iron against multiple low-dose streptozotocin-induced diabetes in rodents. <i>Journal of Cellular Physiology</i> , 2018, 233, 4990-5001.	4.1	2
4	Standardized bovine colostrum derivative impedes development of type 1 diabetes in rodents. <i>Immunobiology</i> , 2017, 222, 272-279.	1.9	6
5	Impaired IL-17 Production in Gut-Residing Immune Cells of 5xFAD Mice with Alzheimer's Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2017, 61, 619-630.	2.6	27
6	Ethyl Acetate Extract of <i>Origanum vulgare</i> L. ssp. <i>hirtum</i> Prevents Streptozotocin-Induced Diabetes in C57BL/6 Mice. <i>Journal of Food Science</i> , 2016, 81, H1846-53.	3.1	13
7	Macrophage migration inhibitory factor is an endogenous regulator of stress-induced extramedullary erythropoiesis. <i>Histochemistry and Cell Biology</i> , 2016, 146, 311-324.	1.7	7
8	Methanolic extract of <i>Origanum vulgare</i> ameliorates type 1 diabetes through antioxidant, anti-inflammatory and anti-apoptotic activity. <i>British Journal of Nutrition</i> , 2015, 113, 770-782.	2.3	55
9	Anti-diabetic actions of carbon monoxide-releasing molecule (CORM)-A1: Immunomodulation and regeneration of islet beta cells. <i>Immunology Letters</i> , 2015, 165, 39-46.	2.5	17
10	Pharmacological inhibition of MIF interferes with trophoblast cell migration and invasiveness. <i>Placenta</i> , 2015, 36, 150-159.	1.5	23
11	The NO-modified HIV protease inhibitor as a valuable drug for hematological malignancies: Role of p70S6K. <i>Leukemia Research</i> , 2015, 39, 1088-1095.	0.8	25
12	In vitro effects of binuclear (η^6 -p-cymene)ruthenium(II) complex containing bridging bis(nicotinate)-polyethylene glycol ester ligand on differentiation pathways of murine Th lymphocytes activated by T cell mitogen. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 575-583.	2.6	7
13	Ruthenium(II) p-cymene complex bearing 2,2'-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response. <i>Journal of Inorganic Biochemistry</i> , 2015, 153, 315-321.	3.5	27
14	In vitro dissection of anti-diabetic effects of compound a, a dissociating glucocorticoid receptor ligand. <i>Archives of Biological Sciences</i> , 2015, 67, 941-947.	0.5	0
15	Carbon Monoxide-Releasing Molecule A1 Inhibits Th1/Th17 and Stimulates Th2 Differentiation <i>In vitro</i> . <i>Scandinavian Journal of Immunology</i> , 2014, 80, 95-100.	2.7	17
16	Saquinavir-NO Inhibits IL-6 Production in Macrophages. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2014, 115, 499-506.	2.5	3
17	Pharmacological application of carbon monoxide ameliorates islet-directed autoimmunity in mice via anti-inflammatory and anti-apoptotic effects. <i>Diabetologia</i> , 2014, 57, 980-990.	6.3	66
18	Study of the anticancer properties of methyl- and phenyl-substituted carbon- and silicon-bridged ansa-titanocene complexes. <i>Journal of Organometallic Chemistry</i> , 2014, 751, 361-367.	1.8	10

#	ARTICLE	IF	CITATIONS
19	Compound A, a selective glucocorticoid receptor agonist, inhibits immunoinflammatory diabetes, induced by multiple low doses of streptozotocin in mice. <i>British Journal of Pharmacology</i> , 2014, 171, 5898-5909.	5.4	16
20	Novel inhibitors of macrophage migration inhibitory factor prevent cytokine-induced beta cell death. <i>European Journal of Pharmacology</i> , 2014, 740, 683-689.	3.5	11
21	The critical role of macrophage migration inhibitory factor in insulin activity. <i>Cytokine</i> , 2014, 69, 39-46.	3.2	21
22	The role of endogenous glucocorticoids in glucose metabolism and immune status of MIF-deficient mice. <i>European Journal of Pharmacology</i> , 2013, 714, 498-506.	3.5	15
23	Differential strain-related tissue immune response to sublethal systemic <i>Aspergillus fumigatus</i> infection in mice. <i>Apmis</i> , 2013, 121, 211-220.	2.0	7
24	Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2013, 262, 72-78.	2.3	7
25	Saquinavir-NO inhibits S6 kinase activity, impairs secretion of the encephalytogenic cytokines interleukin-17 and interferon-gamma and ameliorates experimental autoimmune encephalomyelitis. <i>Journal of Neuroimmunology</i> , 2013, 259, 55-65.	2.3	9
26	Galectin-3 deficiency protects pancreatic islet cells from cytokine-triggered apoptosis in vitro. <i>Journal of Cellular Physiology</i> , 2013, 228, 1568-1576.	4.1	50
27	Phytochemical profile of <i>Rosmarinus officinalis</i> and <i>Salvia officinalis</i> extracts and correlation to their antioxidant and anti-proliferative activity. <i>Food Chemistry</i> , 2013, 136, 120-129.	8.2	263
28	Deficiency of macrophage migration inhibitory factor (MIF) inhibits cytokine-induced IL-1 β generation in murine pancreatic islet cells. <i>Archives of Biological Sciences</i> , 2013, 65, 9-15.	0.5	1
29	The role of macrophage migration inhibitory factor in obesity-associated type 2 diabetes in mice. <i>Archives of Biological Sciences</i> , 2013, 65, 499-505.	0.5	7
30	Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. <i>Cell Cycle</i> , 2012, 11, 1174-1182.	2.6	14
31	Macrophage migration inhibitory factor (MIF) enhances palmitic acid- and glucose-induced murine beta cell dysfunction and destruction in vitro. <i>Growth Factors</i> , 2012, 30, 385-393.	1.7	9
32	Melanoma tumor inhibition by tetrachlorido(O, ω -dibutyl-ethylenediamine-N, ω -di-3-propionate)platinum(IV) complex: in vitro and in vivo investigations. <i>Metallomics</i> , 2012, 4, 1155.	2.4	15
33	Therapeutic Potential of Nitric Oxide-Modified Drugs in Colon Cancer Cells. <i>Molecular Pharmacology</i> , 2012, 82, 700-710.	2.3	28
34	The relevance of the migration inhibitory factor (MIF) for peripheral tissue response in murine sublethal systemic <i>Aspergillus fumigatus</i> infection. <i>Medical Mycology</i> , 2012, 50, 476-487.	0.7	6
35	Platinum(II/IV) complexes containing ethylenediamine-N, ω -di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells. <i>Metallomics</i> , 2012, 4, 979.	2.4	35
36	Cell-type dependent response of melanoma cells to aloe emodin. <i>Food and Chemical Toxicology</i> , 2012, 50, 3181-3189.	3.6	37

#	ARTICLE	IF	CITATIONS
37	Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. <i>Oncology Reports</i> , 2012, 28, 682-688.	2.6	18
38	Macrophage migration inhibitory factor deficiency protects pancreatic islets from palmitic acid-induced apoptosis. <i>Immunology and Cell Biology</i> , 2012, 90, 688-698.	2.3	40
39	Host immune defense against <i>Aspergillus fumigatus</i> : insight from experimental systemic (disseminated) infection. <i>Immunologic Research</i> , 2012, 52, 120-126.	2.9	10
40	Beta cell function: the role of macrophage migration inhibitory factor. <i>Immunologic Research</i> , 2012, 52, 81-88.	2.9	21
41	Resistance to TRAIL and how to surmount it. <i>Immunologic Research</i> , 2012, 52, 157-168.	2.9	48
42	Novel octahedral Pt(IV) complex with di-n-propyl-(S,S)-ethylenediamine-N,N'-di-2-(3-cyclohexyl)propanoate ligand exerts potent immunomodulatory effects. <i>European Journal of Medicinal Chemistry</i> , 2012, 47, 194-201.	5.5	9
43	Novel methylene modified cyclohexyl ethylenediamine-N,N'-diacetate ligands and their platinum(IV) complexes. Influence on biological activity. <i>Journal of Inorganic Biochemistry</i> , 2012, 109, 40-48.	3.5	29
44	Macrophage migration inhibitory factor deficiency protects pancreatic islets from cytokine-induced apoptosis <i>in vitro</i> . <i>Clinical and Experimental Immunology</i> , 2012, 169, 156-163.	2.6	32
45	The immunobiology of apotransferrin in type 1 diabetes. <i>Clinical and Experimental Immunology</i> , 2012, 169, 244-252.	2.6	6
46	In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. <i>Cell Cycle</i> , 2011, 10, 492-499.	2.6	47
47	Differential mechanisms of resistance to sublethal systemic <i>Aspergillus fumigatus</i> infection in immunocompetent BALB/c and C57BL/6 mice. <i>Immunobiology</i> , 2011, 216, 234-242.	1.9	13
48	A role for macrophage migration inhibitory factor in protective immunity against <i>Aspergillus fumigatus</i> . <i>Immunobiology</i> , 2011, 216, 1018-1027.	1.9	26
49	Cytotoxic and immune-sensitizing properties of nitric oxide-modified saquinavir in iNOS-positive human melanoma cells. <i>Journal of Cellular Physiology</i> , 2011, 226, 1803-1812.	4.1	30
50	Multiple antimelanoma potential of dry olive leaf extract. <i>International Journal of Cancer</i> , 2011, 128, 1955-1965.	5.1	48
51	Dry olive leaf extract (DOLE) down-regulates the progression of experimental immune-mediated diabetes by modulation of cytokine profile in the draining lymph nodes. <i>Archives of Biological Sciences</i> , 2011, 63, 289-297.	0.5	0
52	Induction of caspase-independent apoptotic-like cell death of mouse mammary tumor TA3Ha cells in vitro and reduction of their lethality in vivo by the novel chemotherapeutic agent GIT-27NO. <i>Free Radical Biology and Medicine</i> , 2010, 48, 1090-1099.	2.9	10
53	Mechanisms of modulation of experimental autoimmune encephalomyelitis by chronic <i>Trichinella spiralis</i> infection in Dark Agouti rats. <i>Parasite Immunology</i> , 2010, 32, 450-459.	1.5	84
54	Splenic and lung response to nonlethal systemic <i>Aspergillus fumigatus</i> infection in C57BL/6 mice. <i>Medical Mycology</i> , 2010, 48, 735-743.	0.7	10

#	ARTICLE	IF	CITATIONS
55	Dried leaf extract of <i>Olea europaea</i> ameliorates islet-directed autoimmunity in mice. <i>British Journal of Nutrition</i> , 2010, 103, 1413-1424.	2.3	28
56	(S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid "Nitric Oxide (GIT-27NO)" "New Dress for Nitric Oxide Mission.", 2010, , 443-457.		0
57	T cells cooperate with palmitic acid in induction of beta cell apoptosis. <i>BMC Immunology</i> , 2009, 10, 29.	2.2	14
58	MIF in autoimmunity and novel therapeutic approaches. <i>Autoimmunity Reviews</i> , 2009, 8, 244-249.	5.8	81
59	The novel NO-donating compound GIT-27NO inhibits in vivo growth of human prostate cancer cells and prevents murine immunoinflammatory hepatitis. <i>European Journal of Pharmacology</i> , 2009, 615, 228-233.	3.5	15
60	Macrophage migration inhibitory factor stimulates interleukin-17 expression and production in lymph node cells. <i>Immunology</i> , 2009, 126, 74-83.	4.4	82
61	The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1169-1178.	4.1	38
62	Retinoids differentially regulate the progression of autoimmune diabetes in three preclinical models in mice. <i>Molecular Immunology</i> , 2009, 47, 79-86.	2.2	22
63	Time-course changes in ectonucleotidase activities during experimental autoimmune encephalomyelitis. <i>Neurochemistry International</i> , 2009, 55, 193-198.	3.8	36
64	Anticancer Properties of <i>Ganoderma Lucidum</i> Methanol Extracts In Vitro and In Vivo. <i>Nutrition and Cancer</i> , 2009, 61, 696-707.	2.0	67
65	Macrophage migration inhibitory factor (MIF) is necessary for progression of autoimmune diabetes mellitus. <i>Journal of Cellular Physiology</i> , 2008, 215, 665-675.	4.1	76
66	<i>Trichinella spiralis</i> : Modulation of experimental autoimmune encephalomyelitis in DA rats. <i>Experimental Parasitology</i> , 2008, 118, 641-647.	1.2	74
67	Therapeutic effects of combined treatment with ribavirin and tiazofurin on experimental autoimmune encephalomyelitis development: Clinical and histopathological evaluation. <i>Journal of the Neurological Sciences</i> , 2008, 267, 76-85.	0.6	8
68	Ribavirin ameliorates experimental autoimmune encephalomyelitis in rats and modulates cytokine production. <i>International Immunopharmacology</i> , 2008, 8, 1282-1290.	3.8	24
69	Novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid "nitric oxide (GIT-27NO)" induces p53 mediated apoptosis in human A375 melanoma cells. <i>Nitric Oxide - Biology and Chemistry</i> , 2008, 19, 177-183.	2.7	26
70	Anti-tumor effect of <i>Coriolus versicolor</i> methanol extract against mouse B16 melanoma cells: In vitro and in vivo study. <i>Food and Chemical Toxicology</i> , 2008, 46, 1825-1833.	3.6	63
71	Anticancer properties of the novel nitric oxide-donating compound (S,R)-3-phenyl-4,5-dihydro-5-isoxazole acetic acid-nitric oxide in vitro and in vivo. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 510-520.	4.1	68
72	Control of the of the final stage of immune-mediated diabetes by ISO-1, an antagonist of macrophage migration inhibitory factor. <i>Archives of Biological Sciences</i> , 2008, 60, 389-401.	0.5	9

#	ARTICLE	IF	CITATIONS
73	A Potent Immunomodulatory Compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoaxazole Acetic Acid, Prevents Spontaneous and Accelerated Forms of Autoimmune Diabetes in NOD Mice and Inhibits the Immunoinflammatory Diabetes Induced by Multiple Low Doses of Streptozotocin in CBA/H Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 320, 1038-1049.	2.5	32
74	Astrocytes stimulate interleukin-17 and interferon- γ production in vitro. <i>Journal of Neuroscience Research</i> , 2007, 85, 3598-3606.	2.9	44
75	In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. <i>Clinical Immunology</i> , 2007, 123, 311-323.	3.2	61
76	Neutralization of macrophage migration inhibitory factor- α novel approach for the treatment of immunoinflammatory disorders. <i>International Immunopharmacology</i> , 2006, 6, 1527-1534.	3.8	44
77	Strain difference in susceptibility to experimental autoimmune encephalomyelitis between Albino Oxford and Dark Agouti rats correlates with disparity in production of IL-17, but not nitric oxide. <i>Journal of Neuroscience Research</i> , 2006, 84, 379-388.	2.9	49
78	Therapeutic effect of nucleoside analogs on experimental autoimmune encephalomyelitis in dark agouti rats. <i>Archives of Biological Sciences</i> , 2006, 58, 13-20.	0.5	1
79	Combination of Nucleoside Analogues Tiazofurin and Ribavirin Downregulates Experimental Autoimmune Encephalomyelitis. <i>Annals of the New York Academy of Sciences</i> , 2005, 1048, 392-395.	3.8	3
80	Anti-glioma action of aloe emodin: the role of ERK inhibition. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 589-598.	5.4	85
81	Interleukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. <i>Cellular and Molecular Life Sciences</i> , 2005, 62, 2658-2668.	5.4	63
82	Critical Role of Macrophage Migration Inhibitory Factor Activity in Experimental Autoimmune Diabetes. <i>Endocrinology</i> , 2005, 146, 2942-2951.	2.8	115
83	Induction of experimental autoimmune encephalomyelitis in Dark Agouti rats without adjuvant. <i>Clinical and Experimental Immunology</i> , 2004, 136, 49-55.	2.6	51
84	Iron down-regulates macrophage anti-tumour activity by blocking nitric oxide production. <i>Clinical and Experimental Immunology</i> , 2004, 137, 109-116.	2.6	26
85	Astrocyte-induced regulatory T cells mitigate CNS autoimmunity. <i>Glia</i> , 2004, 47, 168-179.	4.9	73
86	Immunosuppressive and anti-inflammatory action of antioxidants in rat autoimmune diabetes. <i>Journal of Autoimmunity</i> , 2004, 22, 267-276.	6.5	23
87	The role of interleukin-17 in inducible nitric oxide synthase-mediated nitric oxide production in endothelial cells. <i>Cellular and Molecular Life Sciences</i> , 2003, 60, 518-525.	5.4	35
88	Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. <i>Journal of Neuroscience Research</i> , 2003, 72, 268-278.	2.9	24
89	Mycophenolic acid inhibits activation of inducible nitric oxide synthase in rodent fibroblasts. <i>Clinical and Experimental Immunology</i> , 2003, 132, 239-246.	2.6	22
90	IMMUNOSUPPRESSANTS LEFLUNOMIDE AND MYCOPHENOLIC ACID INHIBIT FIBROBLAST IL-6 PRODUCTION BY DISTINCT MECHANISMS. <i>Cytokine</i> , 2002, 19, 181-186.	3.2	20

#	ARTICLE	IF	CITATIONS
91	Inhibition of autoimmune diabetes by mycophenolate mofetil is associated with down-regulation of TH1 cytokine-induced apoptosis in the target tissue. <i>Transplantation Proceedings</i> , 2002, 34, 2955-2957.	0.6	7
92	Downregulation of apoptosis in the target tissue prevents low-dose streptozotocin-induced autoimmune diabetes. <i>Molecular Immunology</i> , 2002, 38, 941-946.	2.2	27
93	Down-regulation of experimental allergic encephalomyelitis in DA rats by tiazofurin. <i>Journal of Neuroimmunology</i> , 2002, 130, 66-77.	2.3	16
94	Down-regulation of multiple low dose streptozotocin-induced diabetes by mycophenolate mofetil. <i>Clinical and Experimental Immunology</i> , 2002, 129, 214-223.	2.6	25
95	Leflunomide protects mice from multiple low dose streptozotocin (MLD-SZ)-induced insulinitis and diabetes. <i>Clinical and Experimental Immunology</i> , 2001, 117, 44-50.	2.6	20
96	STAT1 IS REQUIRED FOR iNOS ACTIVATION, BUT NOT IL-6 PRODUCTION IN MURINE FIBROBLASTS. <i>Cytokine</i> , 2001, 13, 179-182.	3.2	39
97	Antidiabetogenic Effect of Pentoxifylline is Associated with Systemic and Target Tissue Modulation of Cytokines and Nitric Oxide Production. <i>Journal of Autoimmunity</i> , 2001, 16, 47-58.	6.5	39
98	Tumor cell-specific inhibition of inducible nitric oxide synthase activation by tiazofurin. <i>International Immunopharmacology</i> , 2001, 1, 795-802.	3.8	1
99	Pentoxifylline Prevents Autoimmune Mediated Inflammation in Low Dose Streptozotocin Induced Diabetes. <i>Autoimmunity</i> , 2001, 8, 213-221.	0.6	14
100	Pentoxifylline inhibits the synthesis and IFN- γ -inducing activity of IL-18. <i>Clinical and Experimental Immunology</i> , 2001, 124, 274-281.	2.6	18
101	Interleukin-17 stimulates inducible nitric oxide synthase activation in rodent astrocytes. <i>Journal of Neuroimmunology</i> , 2001, 119, 183-191.	2.3	88
102	Leflunomide inhibits activation of inducible nitric oxide synthase in rat astrocytes. <i>Brain Research</i> , 2001, 889, 331-338.	2.2	33
103	Differential regulation of nitric oxide production by increase of intracellular cAMP in murine primary fibroblasts and L929 fibrosarcoma cell line. <i>Immunology Letters</i> , 2000, 71, 149-155.	2.5	15
104	Muramyl dipeptide potentiates cytokine-induced activation of inducible nitric oxide synthase in rat astrocytes. Published on the World Wide Web on 2 October 2000. <i>Brain Research</i> , 2000, 883, 157-163.	2.2	5
105	Cell-Specific Inhibition of Inducible Nitric Oxide Synthase Activation by Leflunomide. <i>Cellular Immunology</i> , 2000, 199, 73-80.	3.0	31
106	Modulatory in vitro effects of interleukin-1 receptor antagonist (IL-1Ra) or antisense oligonucleotide to interleukin-1 β converting enzyme (ICE) on acute myeloid leukaemia (AML) cell growth. <i>International Journal of Laboratory Hematology</i> , 1999, 21, 173-186.	0.2	7
107	Pentoxifylline Potentiates Nitric Oxide Production and Growth Suppression in Interferon- γ -Treated L929 Fibroblasts. <i>Cellular Immunology</i> , 1998, 184, 105-111.	3.0	11
108	Interleukin-1 receptor antagonist suppresses experimental autoimmune encephalomyelitis (EAE) in rats by influencing the activation and proliferation of encephalitogenic cells. <i>Journal of Neuroimmunology</i> , 1998, 85, 87-95.	2.3	81

#	ARTICLE	IF	CITATIONS
109	Prevention of experimental autoimmune diabetes in mice by treatment with leflunomide. Transplantation Proceedings, 1998, 30, 4132-4133.	0.6	0
110	Effector Mechanisms in Low-Dose Streptozotocin-induced Diabetes. Autoimmunity, 1998, 6, 119-128.	0.6	130
111	The Inhibitory Effect of Human Macrophage Inflammatory Protein-1 α (LD78) on Acute Myeloid Leukemia Cells in Vitro. Stem Cells, 1996, 14, 445-451.	3.2	4
112	Constitutive production of regulators of stem cell proliferation in the hereditarily anaemic belgrade laboratory (b/b) rat. Comparative Haematology International, 1995, 5, 170-176.	0.5	5
113	Modulation of in vitro T cell alloreactivity by synthetic retinoids. Immunopharmacology, 1994, 27, 87-92.	2.0	12
114	An unusual T-cell surface phenotype in vivo correlates with the failure to proliferate and produce IL-2 in vitro in a patient with common variable immunodeficiency. Clinical Immunology and Immunopathology, 1992, 65, 261-270.	2.0	7
115	In vitro effects of retinoid RO 10-9359 on lectin-induced activation and proliferation of T-lymphocytes. International Journal of Immunopharmacology, 1992, 14, 903-914.	1.1	2
116	Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochemical and Biophysical Research Communications, 1991, 178, 913-920.	2.1	162
117	Modulatory effects of glucocorticoids on immunoregulatory functions of epidermal cells. International Journal of Immunopharmacology, 1987, 9, 577-585.	1.1	10
118	Modulation of Interleukin 1 production by activated macrophages: In Vitro action of hydrocortisone, colchicine, and cytochalasin B. Cellular Immunology, 1982, 69, 235-247.	3.0	73
119	Restoration of impaired immune functions in aging animals. VI. Differential potentiating effect of 2-mercaptoethanol on young and old murine spleen cells. International Journal of Immunopharmacology, 1982, 4, 429-436.	1.1	17